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Abstract
Background
Hydration in advanced cancer is a controversial area; however, current hydration assess-
ments methods are poorly developed. Bioelectrical impedance vector analysis (BIVA) is an
accurate hydration tool; however its application in advanced cancer has not been explored.
This study used BIVA to evaluate hydration status in advanced cancer to examine the asso-
ciation of fluid status with symptoms, physical signs, renal biochemical measures and
survival.
Materials and methods
An observational study of 90 adults with advanced cancer receiving care in a UK specialist
palliative care inpatient unit was conducted. Hydration status was assessed using BIVA in
addition to assessments of symptoms, physical signs, performance status, renal biochemi-
cal measures, oral fluid intake and medications. The association of clinical variables with
hydration was evaluated using regression analysis. A survival analysis was conducted to
examine the influence of hydration status and renal failure.
Results
The hydration status of participants was normal in 43 (47.8%), ’more hydrated’ in 37
(41.1%) and ’less hydrated’ in 10 (11.1%). Lower hydration was associated with increased
symptom intensity (Beta = -0.29, p = 0.04) and higher scores for physical signs associated
with dehydration (Beta = 10.94, p = 0.02). Higher hydration was associated with oedema
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(Beta = 2.55, p0.001). Median survival was statistically significantly shorter in ’less
hydrated’ patients (44 vs. 68 days; p = 0.049) and in pre-renal failure (44 vs. 100 days; p =
0.003).
Conclusions
In advanced cancer, hydration status was associated with clinical signs and symptoms.
Hydration status and pre-renal failure were independent predictors of survival. Further stud-
ies can establish the utility of BIVA as a standardised hydration assessment tool and
explore its potential research application, in order to inform the clinical management of fluid
balance in patients with advanced cancer.
Introduction
People with advanced cancer commonly experience reduced oral intake in the last days of life.
[1] This may cause healthcare professionals and family caregivers to question whether clini-
cally assisted hydration (CAH) is required for the management of hydration status and symp-
toms. However, there is limited evidence to determine the association between hydration and
symptoms in advanced cancer.[2] Physical examination has low sensitivity and specificity for
identifying fluid deficit.[2, 3] The evidence for the use and effects of CAH in advanced cancer
is limited, conflicting and inconclusive.[2, 4, 5]
Bioelectrical impedance analysis (BIA) is a non-invasive body composition assessment tool
based on the flow of electrical current through the body.[6] The recordedmeasurements
include: resistance (R—the restriction to the flow of electrical current through the body, pri-
marily related to the amount of water present in tissue) and reactance (Xc—resistive effect pro-
duced by the tissue interfaces and cell membranes). BIA technology has been used to evaluate
hydration and nutrition in various populations.[2, 7] The impedance index (Height—H (m)2/
R (Ohms)) is the best single predictor of total body water (TBW) in validation studies, includ-
ing cancer populations.[8–19]
The BIA vector analysis (BIVA) RXc graph method involves BIA measurements that are
standardized by height and plotted as bivariate vectors with their confidence intervals (which
are ellipses on the R-Xc plane). The advantage of this method is that it allows for information
to be obtained simultaneously about changes in tissue hydration or soft-tissuemass, indepen-
dent of regression equations, or body weight. BIVA has been used to study hydration in a vari-
ety of different diseases[20–28] and to undertake general body composition assessments in
lung cancer[27, 29] and cancers of the head and neck.[30]
Aim
The aim of this observational study was to use H2/R and BIVA to study the hydration status of
individuals with advanced cancer, in order to determine the relationship of hydration with
symptoms, physical signs, renal biochemicalmeasures and survival.
Materials and Methods
Participants were recruited from a UK specialist palliative care unit betweenDecember 2012
and October 2013. The research project adhered to the requirements of the UK Department of
Health Research Governance Framework. Written consent was obtained from all study partici-
pants; this included consent to report individual patient data in publication. Participant
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consent was recorded in a research recruitment log. This study was approved by the NorthWales
Research Ethics Committee–West (Local research ethics committee approval number = 12/WA/
0200). The eligibility criteria for study entry was: admission to specialist palliative care inpatient
unit; age18 years; cancer (proven by histology or radiological imaging); palliative condition
(no further curative treatment possible); able to understand and communicate in English; serum
urea and creatinine recorded by the clinical team in the previous 72 hours. Our exclusion criteria
were: individuals with implantable defibrillator devices; unable to provide fully informed consent;
active transmissible infections; current use of CAH; current antineoplastic treatment.
Assessments
All assessments were conducted between 9am–12pm. The following information was recorded:
age (years); gender; ethnicity; cancer diagnosis (defined by the International Classification of
Diseases)[31] and primary site of cancer.
Participant observations. A dehydration score was calculated using the approach of Mor-
ita et al,[32] based on a total of scores from three physical findings: oral mucous membranes
moisture (0: moist, 1: somewhat dry, 2: dry), axillarymoisture (0: moist, 1: dry), and sunken-
ness of eyes (0: normal, 1: slightly sunken, 2: sunken). These signs have significant correlations
with biological dehydration,[33–36] with higher scores (range 0–5) indicating an increased risk
of dehydration (previous studies have used a Morita cut-off of 2 to define an increased risk of
dehydration[37, 38]). Performance status was recorded using the Eastern CooperativeOncol-
ogy Group (ECOG) scale (0 = fully active, 5 = dead).[39] Daily fluid intake (0–199mL, 200–
499mL, 500–799 or>800mLs) was recorded using nursing assessments. Height was measured,
without shoes, to the nearest 0.1cm using a portable stadiometer (SECA 213 Height Measure /
Stadiometer). Length was measured in those unable to stand. Body weight was measured to the
nearest 0.1kg (SECA 955 High Capacity Electronic Chair Scale). The following biochemical
measures were recorded: urea (mmol/L), creatinine (μmol/L), estimated glomerular filtration
rate (eGFR) (mL/min/1.73m2), serum sodium (mmol/L), serum albumin (g/L), adjusted cal-
cium (mmol/L) and urine osmolality (mosm/kg).
Hydration questionnaire. Participants completed a hydration symptom questionnaire
(Burge-4 score).[36, 40] This comprised of four questions (thirst, drymouth, unpleasant taste
and fatigue) measuring symptom severity over the previous 24-hours using a 100mmVisual
Analogue Scale (VAS). At the time of the study, the Burge questionnaire was the only available
dehydration symptom assessment tool for advanced cancer patients.
Medication review. The followingmedication information was recorded: the total daily
morphine dose (calculated using opioid-equivalency ratios[41, 42]); use of serotonin reuptake
inhibitors (SSRIs); use of serotonin noradrenaline reuptake inhibitors (SNRIs) and diuretics.
The Anticholinergic Burden (ACB) scale[43, 44] was used to calculate the potential anticholin-
ergic symptom burden from the use of these medications.
Bioelectrical impedance assessments. The EFG3 ElectroFluidGraphVector Impedance
Analyser (Akern) was used for the BIA assessments. The method involved a tetra-polar tech-
nique to deliver a single frequency electrical current of 50kHz (±5%). The external calibration
of the analyser was checked daily using an impedance calibration circuit (R = 470 Ω, Xc = 90
Ω). The testing procedure was conducted in line with methods described by Lukaski[45] and
other recommendations.[46, 47] Participants were lightly clothed, lying in the supine horizon-
tal position, without shoes or socks. Their arms were positioned 30 degrees from the body with
the legs positioned 45 degrees away from each other. Two disposable pre-gelled aluminium
electrodeswere affixed to the dorsum of the right hand (one placed on the edge of an imaginary
line bisecting the ulnar head and the other on the middle finger proximal to the metacarpal-
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phalangeal) and two to the dorsum of the right foot (one placed medially, to an imaginary line
bisecting the medicalmalleolus at the ankle and the other proximal to the metatarsal-phalan-
geal joints).
BIVA point graph analysis. For the BIVA method, the impedance vector (Z) was plotted
as a bivariate vector from its components, R (X axis) and Xc (Y axis), after being standardized
by height (H); this forms two correlated normal random variables (i.e. a bivariate Gaussian vec-
tor).[48, 49] Elliptical probability regions of the mean vector are plotted on the RXc plane
forming elliptical probability regions on the RXc plane, which are tolerance ellipses for individ-
ual vectors and confidence ellipses for mean vectors.[6, 49–52] Tolerance ellipses are the bivari-
ate reference intervals of a normal population for an observation. The RXc graph features three
tolerance ellipses: the median, the third quartile, and the 95th percentile (i.e. 50%, 75% and
95% of individual points).
Participant data were plotted on the RXc point graph using the 50%, 75% and 95% tolerance
ellipses from a non-cancer reference population.[6] Hydration status was determined by the
individual’s baseline bioimpedance vector position on the BIVA RXc normogram. The normo-
gram is a five-point graph (corresponding with the boundaries of each tolerance ellipse).We
simplified the normogram into three parallel sections for this study (Fig 1). Individuals with
vectors falling in (or above) the 51–75% tolerance ellipse (points 1 and 2) were classified as
‘less-hydrated’. Participants with vectors in the central 50th percentile ellipse (point 3) were
classified as ‘normally-hydrated’. Those with vectors in (or below) the lower 51%–75% percen-
tile range (points 4 and 5) were classified as ‘more hydrated’. Participants were compared
according to their hydration status classification (‘less hydrated’ vs. ‘not less hydrated’) to eval-
uate differences in biochemistry, symptoms, clinical signs and fluid intake.
H2/R Analysis. The H2/R was used as a proxy measure of hydration status (i.e. TBW).
Multiple linear regression analysis was conducted to further study the relationship between
several predictor variables with the H2/R. The variables included: patient demographics (age,
gender), clinical measurements (Morita Dehydration Score, oedema presence) serum biochem-
istry (urea:creatinine (ur:cr) ratio) and self-reported symptoms (Burge-4 score). Pre-renal fail-
ure was defined by a ur:cr ratio of100 (mmol/mmol). This biochemical definition was
chosen based on the work of similar studies (NOTE: as creatinine was recorded in μmol/L we
divided this by 1000 to convert to mmol/L to calculate the ur:cr ratio).[3, 53–55] A separate
multiple linear regression analysis involving the Burge-4 score and the assessedmedications
was conducted to determine the potential influence of medications on symptoms.
Sample size calculation
An exploratory sample of 90 patients was chosen to achieve a minimum of 10 subjects for each
item in the regression model. For the RXc graph, a sample size of 90 provides a 95% confidence
region for the mean vector of the vector random variable (Z(R), Z(Xc)) as an ellipse with semi-
axes of approximate lengths of 0.33 and 0.16. For the two-group analysis, a sample size of 45
(for each of the two groups) has power of 0.8 for detecting a difference of (0.5, 0.5) in the mean
BIVA vectors between groups, for significance level of 0.05.[56]
Statistical analysis
The primary focus of this study was to use the H2/R and BIVA to evaluate the relationship of
hydration status with physical signs, symptoms, biochemicalmeasures and survival. Statistical
Package for the Social Sciences (SPSS) version 21.0 was used for standard calculations. Distri-
butions of all variables were assessed for normality using the Shapiro-Wilk test. Parametric and
non-parametric tests were used as appropriate. Frequency analysis was conducted to compare
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differences between groups and variables using the chi-squared test, Student t test and the
Mann-Whitney U test. For the independent t-tests, Levene’s test for homogeneity of variance
was used to examine the quality of variances within a population to identify whether deriva-
tives required exclusion or separate analysis from the cohort. Multiple linear regression analy-
sis was used to evaluate associations between variables. The significance level was set at <0.05.
The BIVA statistical analysis was conducted using software developed by Professor Antonio
Piccoli, University of Padova.[57] Hotelling’s T2 test for vector analysis was used to compare
for significant difference betweenmean vector distances.
Fig 1. Classification of hydration status using the RXc graph and the 50th and 75th percentile tolerance
ellipses. The 50% and 75% percentiles were used to project a 5-point hydration scale on the BIA normogram.
Positions 1 and 2 = ‘less hydrated’ individuals; position 3 = ‘normally hydrated’ individuals; positions 4 and 5 =
‘more hydrated’ individuals.
doi:10.1371/journal.pone.0163114.g001
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Survival was evaluated from baseline assessment to death. All patients were followed up for
3-months following completion of the study. Kaplan-Meier analysis was used to analyse sur-
vival, according to the hydration status and renal failure status. A Cox proportional hazards
model was used to assess the effect of the ur:cr ratio and the H2/R on survival, with adjustment
for demographic characteristics, baseline ECOGperformance status and cancer type.
Results
Demographics
Ninety patients (males = 42, 46.7%; females = 48, 53.3%) participated (recruitment
rate = 76.3%) (Fig 2). The mean age of participants was 71.2 years (SD± 12.21) and were mostly
Caucasian (n = 89, 98.9%) (Table 1). Twenty-one different types of cancers (in addition to 4
(4.4%) unknowns) were recorded; lung cancer was the most common (n = 14, 15.6%). Most
participants had an ECOGperformance status of 3 (n = 36, 40%).
Clinical assessments
The baseline assessments are presented in Table 2. Most participants had a daily oral fluid intake
of approximately 500–799mLs (n = 42, 46.7%). Pre-renal failure was present in 37 (41.1%)
patients and mean eGFRwas 72.1 mL/min/1.73m2. The highest symptom score was recorded for
fatigue (M = 63.60, SD = 30.09). The mean Burge-4 score was 222.07mm (SD = 95.40) and ran-
ged from 0 to 400mm. The Morita Dehydration Score was2 in 52 (57.8%) participants.
Multiple linear regression analysis
The H2/R was significantly predicted by female gender (Beta = -13.85, p<0.001), symptoms
(the Burge-4 score) (Beta = -0.29, p = 0.04), physical signs (the Morita Dehydration Score)
(Beta = -2.55, p = 0.02) and oedema (Beta = 10.94, p<0.001) (Table 3). A separate regression
analysis demonstrated that opioids, diuretics, anticholinergics, SNRIs and SSRIs medications
were not statistically significant in predicting symptoms (Burge-4 score).
Hydration assessment and BIVA
Hydration status was normal in 43 (47.8%), ‘more-hydrated’ in 37 (41.1%) and ‘less hydrated’
in 10 (11.1%) (Figs 3 and 4; Table 4). We simplified the hydration status classifications to com-
pare ‘less-hydrated’ participants (n = 10, 11.1%) to those ‘not less hydrated’ (n = 80, 88.9%).
This comparison demonstrated that oral fluid intake was statistically significantly lower in ‘less
hydrated’ participants compared to those ‘not less hydrated’ (p = 0.04) (Table 5). Additionally,
axilla dryness scored significantly higher in those ‘less hydrated’ compared to those ‘not less
hydrated’ (p = 0.02). No other statistically significant differences were detected for the current
sample. The analysis demonstrated non-significant differences between the groups, with ‘less
hydrated’ individuals reporting higher values (when compared to the ‘not less hydrated’ group)
for symptoms (the Burge-4 sub-scores), the Morita Dehydration Score, the ur:cr ratio, urinary
osmolality and ECOG.
Survival analysis
Seventy-six (84.4%) participants died before the end of the follow-up period.Median survival for
the sample was 62 days (Table 6). Median survivalwas shortest in ‘less hydrated’ participants (44
days) and longest in those ‘more hydrated’ (70 days). Survivalwas statistically significantly shorter
when ‘less hydrated’ participants were compared to those ‘not less hydrated’ (44 days vs. 68 days,
hazard ratio = 2.01 [95% Confidence Interval (CI) = 1.00, 4.02]; p = 0.049) (Fig 5). Participants
The Association of Hydration Status with Physical Signs, Symptoms and Survival in Advanced Cancer
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with pre-renal failure had shorter survivalwhen compared to those without pre-renal failure (44
days vs. 100 days, hazard ratio = 2.03 [95%CI = 1.26, 3.26]; p = 0.003) (Fig 6).
The H2/R and the ur:cr ratio remained significant predictors of survival following statistical
adjustment (cox regression) for age, sex, baseline ECOGperformance status and cancer type
Fig 2. Recruitment flowchart. Flowchart representation of the number of individuals recruited to the study.
doi:10.1371/journal.pone.0163114.g002
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(Table 7). Cancer type also significantly influenced survival p = 0.02. The hazard ratio for
death according to the H2/R was 0.98 [95%CI = 0.96, 1.00] (p = 0.04); this means each unit
m2/Ohm increase of the H2/R was associated with reduced probability of death by a factor of
1.02 (i.e. 1/hazard ratio). The hazard ratio for death according to the ur:cr ratio was 1.01 [95%
CI = 1.00, 1.02], p = 0.001; this means that each unit increase (mmol:mmol) of the ur:cr ratio
was associated with an increased probability of death by a factor of 0.99.
Table 1. Demographic details of study participants.
Characteristic N (Data presented as mean or %)
Mean age ( SD), years 71.17 (12.21)
Male 42 (46.7)
Female 48 (53.3)
Mean height ( SD), cm 164.22 (9.6)
Mean weight ( SD), kg 69.45 (17.9)
Mean body mass index ( SD), kg/m2 25.17 (4.98)
Race/ethnicity
Caucasian 89 (98.9)
Other 1 (1.1)
ECOG
0: Asymptomatic 0 (0)
1: Symptomatic but completely ambulatory 15 (16.7)
2: Symptomatic, 50% in bed during the day 22 (24.4)
3: Symptomatic, !50% in bed, but not bedbound 36 (40.0)
4: Bedbound 17 (18.9)
Cancer diagnosis
Lung 14 (15.6)
Colorectal 11 (12.2)
Prostate 10 (11.1)
Ovarian 6 (6.7)
Breast 6 (6.7)
Oesophageal 5 (5.6)
Myeloma 5 (5.6)
Pancreatic 4 (4.4)
Unknown 4 (4.4)
Cervical 3 (3.3)
Mesothelioma 3 (3.3)
Gastric 3 (3.3)
Brain 3 (3.3)
Melanoma 2 (2.2)
Soft tissue/muscle/connective tissue 2 (2.2)
Biliary 2 (2.2)
Lymphoma 2 (2.2)
Bladder 1 (1.1)
Liver 1 (1.1)
Groin 1 (1.1)
Uterus 1 (1.1)
Tongue 1 (1.1)
Table 1 shows the details of age, gender, height, weight, body mass index, performance status and cancer
diagnosis.
doi:10.1371/journal.pone.0163114.t001
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Discussion
Main findings and new knowledge
This is the first study to use BIVA to evaluate hydration and its relationship with symptoms
and survival in advanced cancer patients. The findings demonstrate that hydration (as mea-
sured by H2/R and BIVA) in advanced cancer was significantly associated with physical signs
(mucous membrane moisture, axilla dryness, sunken eyes, oedema), symptoms (drymouth,
thirst, unpleasant taste, fatigue) and oral fluid intake. Survival was statistically significantly
shorter in ‘less-hydrated’ individuals and those with pre-renal failure.
Comparison with previous work
Our data demonstrates that the Morita Dehydration Score was associated with hydration
status, which supports previous work using this tool to assess physical signs of hydration.
[32] In this study, women had a lower H2/R compared to men, which suggests comparatively
Table 2. Study baseline results.
Variable N Mean (M) SD Range (min–max) Normal reference range (min–max)
Biochemical results
Sodium (mmol/L) 89 136.12 4.28 126–145 133–146
Urea (mmol/L) 90 7.26 4.36 1.3–33.8 2.5–7.8
Creatinine (ȝmol/L) 90 79.26 30.33 23–183 50–130
eGFR (mL/min/1.73m2) 90 72.1 18.77 24–90 0–90
Ur:cr ratio (mmol/mmol) 90 96.68 53.16 32.61–383.61
Pre-renal failure: Ur:cr ratio100 (%) 37 (41.1)
Adjusted calcium (mmol/L) 89 2.32 0.24 1.65–3.5 2.20–2.60
Serum albumin (g/L) 90 32.07 6.08 3–47 35–50
Serum osmolarity (mmol/kg) 61 286.36 10.03 260–311 275–295
Urine osmolarity (mmol/kg) 22 511.77 202.83 174–951 250–750
Bioelectrical impedance
R/H (Ohm/m) 90 341.58 82.22
Xc/H (Ohm/m) 90 27.68 9.49
PA (degrees) 90 4.71 1.33
H2/R (m2/Ohm) 90 51.58 15.41
Morita Dehydration Score
2 (%) 38 (42.2)
2 (%) 52 (57.8)
Burge-4 score (mm)
Total score (mm) 90 222.07 95.40 0–400
Thirst (mm) 90 56.11 29.49 0–100
Dry mouth (mm) 90 60.01 30.64 0–100
Unpleasant taste (mm) 90 42.34 34.11 0–100
Fatigue (mm) 90 63.60 30.09 0–100
Daily oral fluid intake
0–499mLs (%) 27 (30.0)
500–799mLs (%) 42 (46.7)
800mLs (%) 21 (23.3)
Table 2 shows descriptive statistics of biochemical results, bioelectrical impedance, physical signs (Morita Dehydration Score), symptoms (Burge-4 score)
and daily oral fluid intake.
doi:10.1371/journal.pone.0163114.t002
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lower hydration volume. This finding is consistent with previous work[6, 51] and human
physiology,[6, 51, 58, 59] as women normally have more body fat than men and therefore com-
paratively have less body water in proportion to their weight.[58, 59] Oedematous participants
had higher H2/R compared to non-oedematous participants, which suggests they had an
increased hydration volume. Although these findings are consistent with the literature it is not
possible to determine intracellular or extracellular volumes without the use of regression equa-
tions; however, these equations have methodological limitations in advanced cancer.[24, 25,
60–62]
Our study demonstrates how higher Burge-4 scores were associated with lower H2/R (which
suggests comparatively lower TBW volume). Consequently, our data supports previous work
concerning the assessment of dehydration symptoms in advanced cancer[36, 40] and non-can-
cer populations.[63–67] Our analysis demonstrates that lower oral fluid intake was associated
with ‘less hydrated’ patients. However, we are unable to determine whether this reduction in
oral intake contributed to the participant’s hydration volume, or if it was the result of their clin-
ical condition.
Previous estimates of cancer dehydration prevalence are generally based on biochemical cri-
teria with the prevalence reported to be 60–75%.[68, 69] In this study, only 11.1% of partici-
pants were ‘less-hydrated’ and 41.1% were ‘more hydrated’. Comparatively, the prevalence of
pre-renal failure in this study was 41.1%, which is consistent with previous work.[54] Our find-
ings demonstrated that (in this sample) individuals were more likely to be ‘more hydrated’ as
opposed to ‘less hydrated’. This may suggest that biochemical definitions of dehydration lack
sensitivity in people with advanced cancer. Furthermore, the regression analysis did not detect
a statistically significant association between the ur:cr ratio and the H2/R variables (Table 3).
This data supports previous work that demonstrates how biochemicalmeasures poorly corre-
late with symptoms (drymouth, thirst, fatigue and unpleasant taste) in advanced cancer.[2, 3,
33, 53, 69, 70] This provides evidence that biochemicalmeasures lack sensitivity to predict
hydration-related symptoms in advanced cancer.
Table 3. Multiple linear regression analysis of the impedance index (H2/R).
Variable Beta (standard error) P
Constant 96.96 (10.02) 0.001
Age 0.13 (0.11) 0.246
Female -13.85 (2.52) 0.001
ECOG -0.55 (1.38) 0.692
Oedema present 10.94 (2.89) 0.001
Urea:creatinine ratio -0.02 (0.02) 0.423
Morita Dehydration Score -2.55 (1.1) 0.023
Burge-4 score -0.29 (0.14) 0.038
R 0.71
R squared 0.50
Adjusted R squared 0.45
Standard error of estimate 11.38
Durbin-Watson 1.74
No. of observations 90
Table 3 shows the multiple linear regression analysis to model the relationship between the impedance
index (H2/R) and predictor variables (age, gender, Morita Dehydration Score, oedema presence, urea:
creatinine ratio and the Burge-4 score).
doi:10.1371/journal.pone.0163114.t003
The Association of Hydration Status with Physical Signs, Symptoms and Survival in Advanced Cancer
PLOS ONE | DOI:10.1371/journal.pone.0163114 September 27, 2016 10 / 20
Survival
Our data demonstrates that pre-renal failure was associated with shorter survival in patients
with advanced cancer, which is consistent with previous research.[71] Similarly, the Prognosis
in Palliative care Study (PiPS) reported how an elevated urea measurement was a predictor of
shorter survival in patients with advanced cancer.[72] We are unable to determine the exact
reason for the association of shorter survival with lower H2/R and BIVA hydration status.
However, it is possible that ‘less hydrated’ individuals were more likely to have a clinical picture
that was associated with shorter survival (e.g. cachexia).
Limitations
This study describes a small, predominantly Caucasian, specialist palliative care population in
the last two months of life. Only ten participants were ‘less hydrated’, which meant that the
two-group analysis was statistically limited. Consequently, the ability to extrapolate the results
of this analysis to other population groups is limited. This study was observational and there-
fore is unable to determine causation of the studied variables. This analysis involved many
Fig 3. Vector positions for males on the RXc point graph (N = 42). Values for male participants are illustrated
by circles on the 50%, 75%, and 95% bioimpedance tolerance ellipses of the reference population.
doi:10.1371/journal.pone.0163114.g003
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different cancers at various stages of illness. Survival was significantly influenced by cancer
type, meaning some participants experienced shorter survival on account of their diagnosis.
Consequently, the exact influence of hydration on survival is difficult to determine. Further-
more, it is possible that pre-existing differences (related to the different cancers) may have
caused variation in the body composition of participants. Although the H2/R is the single best
Fig 4. Vector positions for females on the RXc point graph (N = 48). Values for female participants are
illustrated by triangles on the 50%, 75%, and 95% bioimpedance tolerance ellipses of the reference population.
doi:10.1371/journal.pone.0163114.g004
Table 4. Classification of hydration as a three-item scale according to the RXC graph scale.
Hydration status Male Female Total (%)
Normal 18 25 43 (47.8)
‘Less hydrated’ 7 3 10 (11.1)
‘More hydrated’ 17 20 37 (41.1)
Total 42 48 90
Table 4 shows the hydration status of participants according to the position of individual vectors on the RXc
graph scale.
doi:10.1371/journal.pone.0163114.t004
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predictor of TBW we are unable estimate fluid volume without the use of regression equations
(which improve the accuracy of TBWmeasurement but are methodologically limited in can-
cer). Additionally, the BIVA method is unable to distinguish between fluid compartments or
Table 5. Comparison between ‘less hydrated’ and ‘not less hydrated’ groups.
‘Less hydrated’ (n = 10) ‘Not less hydrated’ (n = 80)
Variable Mean SD Mean SD T test p
Burge-4 score (mm) 257.60 91.76 217.63 95.47 1.25 0.21
Thirst 72.70 22.97 54.04 29.67 1.92 0.06
Dry mouth 70.60 25.80 58.69 31.07 1.16 0.25
Unpleasant taste 52.20 37.51 41.11 33.71 0.97 0.34
Fatigue 62.10 23.73 63.79 30.92 -0.17 0.87
Ur:Cr ratio (mmol/mmol) 137.15 101.33 91.62 42.20 1.41 0.19
Na (mmol/L) (n = 89) 134.10 4.77 136.38 4.17 -1.60 0.11
eGFR (mL/min/1.73m2) 71.00 24.68 72.24 18.09 -0.20 0.85
AdjCa (mmol/L) (n = 61) 2.26 0.13 2.32 0.25 -0.81 0.42
Serum osmalilty (mosm/kg) 281.75 18.46 286.68 9.38 -0.95 0.35
Albumin (g/L) 29.70 3.95 32.36 6.25 -1.31 0.19
Urine osmolality (mosm/kg) (n = 61) 540.50 177.03 505.39 212.25 0.31 0.76
H2/R (m2/Ohm) 39.57 9.28 53.08 15.40 -2.71 0.008
Mann U Whitney test variable Mean Rank Mean Rank Z P
ECOG 52.90 529.00 44.58 3566.00 326 0.32
Oral intake (mLs) 31.25 312.5 47.28 3782.50 257.5 0.04
Morita Dehydration Score 58.60 586.00 43.86 3509.00 269 0.08
Mucous 52.45 524.50 44.63 3570.50 330.5 0.34
Axilla dryness 61.00 610.00 43.56 3485.00 245 0.02
Sunken eyes 44.90 449.00 45.58 3646.00 394 0.92
Table 5 shows a comparison between the ‘less hydrated’ and the ‘not less hydrated’ groups according to symptoms (Burge-4 score), biochemical
measures, performance status (ECOG), oral fluid intake and physical symptoms (Morita Dehydration Score).
doi:10.1371/journal.pone.0163114.t005
Table 6. Univariate survival analysis of participants according to hydration status and pre-renal fail-
ure classifications.
Subgroup Median survival in
days
Hazard ratio (95%
CI)
p
Overall 62.0
Hydration classification according to three BIVA
classifications
Normal 68.0 1.00 (ref) 0.09
‘Less hydrated’ 44.0 2.01 (1.00, 4.02) 0.11
‘More hydrated’ 70.0 0.72 (0.45, 1.15) 0.34
Hydration classification according to two BIVA
classifications
‘Not less hydrated’ 68.0 1.00 (ref)
‘Less hydrated’ 44.0 2.01 (1.00, 4.02) 0.049
Pre-renal failure present?
No 100.0 1.00 (ref)
Yes 44.0 2.03 (1.26, 3.26) 0.003
Table 6 shows the survival analysis data for participants according to hydration status and pre-renal failure
classifications.
doi:10.1371/journal.pone.0163114.t006
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define intracellular and extracellular fluid volumes, which limits our ability to study these dif-
ferences in greater detail.
What is the significance of the findings of this analysis?
This analysis provides evidence that hydration status is related to physical signs (mucous mem-
brane moisture, axilla dryness, sunken eyes, oedema), symptoms (drymouth, thirst, unpleasant
taste, fatigue), oral fluid intake and survival in an advanced cancer population. These variables
can potentially be used to develop criteria for the assessment of hydration status, for the
Fig 5. Kaplan-Meier graph showing survival time in days according to the ‘less hydrated’ classification (ġ2 = 4.08, P = 0.04). Tick marks indicate
censoring of data.
doi:10.1371/journal.pone.0163114.g005
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purposes of research and clinical practice. Our data reports no statistically significant associa-
tion between biochemicalmeasures and hydration status. Furthermore, we report that (in this
sample) a greater number of participants were ‘more-hydrated’ compared to those ‘less-
hydrated’. Consequently, we recommend that healthcare professionals should carefully assess
hydration status in their patients; it may be possible for individuals to be at risk of fluid over-
load even though the biochemical results indicate pre-renal failure. However, we are unable to
provide recommendations for the use (or non use) of CAH as this was beyond the scope of this
research study.
Fig 6. Kaplan-Meier graph showing survival time in days according to the presence or absence of pre-renal failure (ġ2 = 8.99, P = 0.003). Tick
marks indicate censoring of data.
doi:10.1371/journal.pone.0163114.g006
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Future opportunities and research possibilities
Future studies can build on this work and use BIVA to study hydration status according to specific
cancers, stratified by performance status, stage of illness, ethnicity and gender. The non-invasive
properties of BIVA provide the potential to conduct longitudinal assessments to study hydration
and symptoms over time [28] (e.g. the dying phase), in order to determine the clinical utility of
CAH. Further studies can examine the potential use of bioimpedance for prognostication.
Conclusions
In advanced cancer, hydration status (classified by BIA/BIVA) relates to clinically measurable
signs and symptoms. Hydration status and pre-renal failure were independent predictors of
survival. Further studies can establish the utility of BIVA as a standardised hydration assess-
ment tool and explore its potential research application, in order to inform the clinical manage-
ment of fluid balance in patients with advanced cancer.
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Table 7. Multivariate cox regression analysis for death according to age, performance status, cancer
type, the ur:cr and the H2/R.
Variable Hazard Ratio (95% CI) p
Age (years) 0.99 (0.97, 1.02) 0.52
Female 0.84 (0.47, 1.51) 0.56
ECOG 1 0.06
ECOG (2 vs. 1) 1.69 (0.72, 3.96) 0.23
ECOG (3 vs. 1) 2.82 (1.22, 6.54) 0.02
ECOG (4 vs. 1) 3.07 (1.17, 8.07) 0.02
Cancer type (GI) 0.02
Cancer type (Gyne vs. GI) 0.40 (0.13, 1.24) 0.11
Cancer type (Lung vs. GI) 1.35 (0.67, 2.75) 0.41
Cancer type (Misc vs. GI) 0.41 (0.20, 0.83) 0.01
Cancer type (GU vs GI) 0.42 (0.18, 1.00) 0.05
Ur:Cr (mmol/mmol) 1.01 (1.00, 1.02) 0.001
H2/R (m2/Ohm) 0.98 (0.96, 1.00) 0.04
Table 7 shows the cox regression analysis for death (hazard ratio) according to age, performance status
(ECOG), cancer type, the ur:cr and H2/R. Abbreviations: GI = gastrointestinal; Gyne = gynecological;
Misc = miscellaneous; GU = genitourinary.
doi:10.1371/journal.pone.0163114.t007
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